{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:45:34Z","timestamp":1778809534315,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011957","name":"Takeda Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clml.2019.05.007","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T11:03:06Z","timestamp":1557745386000},"page":"480-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation"],"prefix":"10.1016","volume":"19","author":[{"given":"Vamsi","family":"Kota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.05.007_bib1","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clml.2019.05.007_bib2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2019.05.007_bib3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib4","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clml.2019.05.007_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.05.007_bib6","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1182\/blood-2018-99-118026","article-title":"Long-term follow-up after treatment discontinuation in patients with chronic myeloid leukemia: the Korean Imatinib Discontinuation (KID) study [abstract]","volume":"132","author":"Zang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib7","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.05.007_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2018-99-112982","article-title":"Imatinib Suspension and Validation (ISAV) study: final results at 79 months [abstract]","volume":"132","author":"Mori","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib9","author":"Saglio"},{"key":"10.1016\/j.clml.2019.05.007_bib10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.007_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2019.05.007_bib12","author":"Hughes"},{"key":"10.1016\/j.clml.2019.05.007_bib13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","article-title":"Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan","volume":"103","author":"Takahashi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.05.007_bib14","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2018-99-116563","article-title":"Updated 18-month results from DASFREE: a study evaluating dasatinib discontinuation in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) and deep molecular response (DMR) [abstract]","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib15","first-page":"314","article-title":"Dasatinib discontinuation in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DASFREE) [abstract]","volume":"130","author":"Shah","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12885-018-4273-1","article-title":"Design and rationale for the Life After Stopping Tyrosine Kinase Inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia","volume":"18","author":"Atallah","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2019.05.007_bib18","first-page":"2903","article-title":"Results from the US Life After Stopping TKIs (LAST) study [abstract]","volume":"130","author":"Atallah","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib19","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2019.05.007_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib23","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2014.56.3858","article-title":"Reply to J. Richter et\u00a0al","volume":"32","author":"Rousselot","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.05.007_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2019.05.007_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.05.007_bib29","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukemia: EMSO clinical practice guidelines for diagnosis, treatment, and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib30","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.05.007_bib31","series-title":"Tasigna (nilotinib) [package insert]","year":"2018"},{"key":"10.1016\/j.clml.2019.05.007_bib32","series-title":"Tasigna (nilotinib) [summary of product characteristics]","year":"2018"},{"key":"10.1016\/j.clml.2019.05.007_bib33","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib34","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.007_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein\u2013tyrosine kinase inhibitor STI571 inhibits in\u00a0vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2019.05.007_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib37","first-page":"PB1759","article-title":"PDGFRb sustains the \u201cwithdrawal syndrome\u201d after imatinib discontinuation [abstract]","volume":"100","author":"Galimberti","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.05.007_bib38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.leukres.2009.01.040","article-title":"The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism","volume":"33","author":"Breccia","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.05.007_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13395-018-0150-5","article-title":"Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation","volume":"8","author":"Contreras","year":"2018","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.clml.2019.05.007_bib40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","article-title":"Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: a patient-based survey on 1133 patients","volume":"39","author":"Breccia","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.05.007_bib41","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood.V124.21.4547.4547","article-title":"Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR) [abstract]","volume":"124","author":"Boquimpani","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib42","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00432-016-2159-7","article-title":"Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia","volume":"142","author":"Jiang","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.007_bib43","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/10428194.2017.1337114","article-title":"Patient perceptions of treatment-free remission in chronic myeloid leukemia","volume":"59","author":"Villemagne Sanchez","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.05.007_bib44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/10428194.2015.1049166","article-title":"Change of health-related profiles after imatinib cessation in chronic phase chronic myeloid leukemia patients","volume":"57","author":"Park","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.05.007_bib45","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood.V128.22.3066.3066","article-title":"Patient-reported quality of life before and after stopping treatment in the ENESTfreedom trial of treatment-free remission for patients with chronic myeloid leukemia in chronic phase [abstract]","volume":"128","author":"Hochhaus","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib46","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.V128.22.1891.1891","article-title":"Patient-reported quality of life before and after stopping treatment in the ENESTop trial of treatment-free remission for patients with chronic myeloid leukemia in chronic phase [abstract]","volume":"128","author":"Mahon","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.007_bib47","first-page":"1598","article-title":"Impact of treatment cessation on overall disease outcomes in patients with chronic myeloid leukemia in chronic phase (CML-CP) attempting treatment-free remission (TFR): findings from ENESTfreedom and ENESTop [abstract]","volume":"130","author":"Saglio","year":"2017","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:25Z","timestamp":1761870745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019301673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S2152265019301673"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}